Jaguar Health, Inc.
JAGX
Positions held
Your positionsJAGX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $8.81M | Enterprise value | $14.38M | Trailing P/E | — | Forward P/E | -0.80 |
| PEG | — | Price / book | 3.33 | Beta | -0.11 | Dividend yield | 0.00% |
| Revenue growth | -58.9% | Earnings growth | — | Gross margin | 82.3% | Operating margin | -6.2% |
| Profit margin | -130.8% | ROE | -5.5% | ROA | -38.0% | Debt / equity | 2.53 |
| Current ratio | 0.74 | Free cash flow | -$1.78M | Analyst recommendation | none | Mean target | — |
| 52w high | $1,260.00 | 52w low | $2.35 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | $20.2M | $3.2M | $3.1M | $3.0M | — |
| Op margin | -620.2% | 50.3% | -631.9% | -234.8% | -268.8% | — |
| Net income | -$12.7M | $8.8M | -$23.1M | -$9.5M | -$10.4M | — |
| Gross margin | 15.8% | 94.3% | 32.0% | 82.7% | 82.3% | — |
| Gross profit | $0.2M | $19.1M | $1.0M | $2.6M | $2.5M | — |
| Operating income | -$7.6M | $10.2M | -$20.4M | -$7.2M | -$8.0M | — |
- Revenue -94% vs prior quarter ($1.2M vs $20M).
- Gross margin 15.8% (was 94.3% prior quarter).
- Operating margin compressed to -620.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | — |
| Op margin | -391.9% | -263.8% | -347.5% | -287.8% | — |
| Net income | -$53.4M | -$38.5M | -$41.3M | -$47.5M | — |
| Gross margin | 67.2% | 83.3% | 79.1% | 83.1% | — |
| Gross profit | $7.7M | $9.7M | $7.7M | $9.9M | — |
| Operating income | -$45.1M | -$30.8M | -$33.9M | -$34.4M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances
2026-10-03 · Jaguar Health Announces a Special Stock Dividend
2026-09-29 · Napo Pharmaceuticals Crofelemer Study Accepted for Presentation at ACG 2026
2026-09-25 · Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
2026-09-24 · Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
2026-09-23 · Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
2026-09-23 · Top Premarket Decliners
2026-09-23 · JAGX Stock Soars Over 10% Premarket After Best Day In Over 8 Years: What’s Driving The Surge?
2026-09-22 · Top Midday Gainers
2026-09-22 · Jaguar Health Receives Fee Waivers from FDA
Price (daily)
Full chart · RSI · MACD · patterns